GlassScriptPhysician profile
Ramis Gheith
NPI 1063611895
$72,875.99
in general payments reported to CMS, 2019-2025
34 companies · $11K in 2025
The $11K reported for 2025 was more than what 95% of Interventional Pain Medicine providers received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $19K · 2020: $1,014 · 2021: $3,717 · 2022: $11K · 2023: $7,036 · 2024: $20K · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $26K · Food and Beverage: $7,227 · Travel and Lodging: $4,454 · Entertainment: $265.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $26,243.75 |
| Food and Beverage | $7,226.88 |
| Travel and Lodging | $4,454.01 |
| Entertainment | $265.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zavation Medical Products, LLC | $27,472.40 | 2023-2025 | |
| Vertos Medical, INC. | $16,602.83 | 2019-2023 | Mild Device Kit |
| Boston Scientific Corporation | $5,317.20 | 2019-2024 | Wavewriter Alpha Prime 16 |
| Corelink, LLC | $4,959.07 | 2021-2023 | |
| Nevro Corp. | $3,483.52 | 2019-2024 | Senza |
| Vertiflex, INC. | $2,424.56 | 2019 | |
| Abbott Laboratories | $2,404.98 | 2019-2025 | Proclaim, Eterna |
| Spinal Simplicity, LLC | $2,174.58 | 2021-2022 | |
| Globus Medical, INC. | $1,356.01 | 2025 | Senza, Omnia, Corridor |
| Xtant Medical INC | $1,061.81 | 2024 | |
| Relievant Medsystems, INC. | $837.67 | 2019-2022 | |
| Flowonix Medical Incorporated | $804.86 | 2019-2020 | |
| Foundation Fusion Solutions, LLC | $675.56 | 2021-2025 | |
| Medtronic, INC. | $560.98 | 2021-2025 | Intellis Adaptivestim, Synchromedii |
| Medtronic USA, INC. | $489.55 | 2019-2020 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Saluda Medical Americas, INC. | $429.80 | 2025 | Evoke |
| Si-Bone, INC. | $310.25 | 2024 | |
| Merit Medical Systems INC | $237.44 | 2022-2023 | Star Tumor Ablation System, Stabilit System |
| Tersera Therapeutics LLC | $216.55 | 2019-2020 | |
| Stimwave Technologies Incorporated | $180.43 | 2019 | |
| Nalu Medical, INC. | $159.29 | 2021-2022 | |
| Curonix LLC | $120.80 | 2024-2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Painteq LLC | $112.95 | 2024 | Painteq |
| Axogen | $107.98 | 2022 | |
| Spr Therapeutics, INC | $102.58 | 2025 | Sprint Pns System |
| Kci USA, INC. | $66.08 | 2019 | |
| Averitas Pharma INC. | $60.50 | 2023 | Qutenza |
| Depuy Synthes Sales INC. | $36.79 | 2019 | |
| Biotronik Nro, INC. | $34.44 | 2025 | Prospera |
| Vertex Pharmaceuticals Incorporated | $18.27 | 2025 | |
| Assertio Therapeutics, INC. | $17.06 | 2019 | |
| Bioventus LLC | $13.82 | 2022 | |
| Sentynl Therapeutics, INC. | $13.30 | 2019 | |
| Collegium Pharmaceutical, INC. | $12.08 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ramis Gheith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.